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Introduction {#sec1}
============

The hippocampal dentate gyrus and its mossy fiber (MF) output have been implicated in the pathophysiology of neuropsychiatric disorders and in their therapeutic treatments ([@bib21], [@bib8], [@bib54]). Particular attention has been paid to their possible involvement in the mechanism of action of electroconvulsive treatment (ECT). ECT has a broad therapeutic potential for psychiatric disorders and is well known to have a fast-acting antidepressant effect ([@bib13]). ECT rapidly causes molecular and/or functional changes in the dentate gyrus and at the synapse made by MF onto CA3 pyramidal cells ([@bib41], [@bib49], [@bib15], [@bib28]). One characteristic functional feature of the MF-CA3 synapse is its dynamic regulation by various kinds of neuromodulators including monoamines ([@bib18], [@bib22]). Among monoamines, serotonin and dopamine induce robust potentiation of the MF synaptic transmission ([@bib29], [@bib25]). These monoaminergic modulations show marked alterations after antidepressant drug administration or ECT in mice ([@bib25], [@bib26], [@bib23], [@bib24], [@bib28]) and also in mouse models of neuropsychiatric disorders including schizophrenia and epilepsy ([@bib30], [@bib43], [@bib50]), suggesting possible roles in both therapeutic treatments and pathophysiology of neuropsychiatric disorders. The potentiating effects of serotonin and dopamine are mediated by 5-HT~4~ and D~1~-like receptors, respectively ([@bib29], [@bib25]). Both of these receptors are coupled to the Gs-cAMP-dependent intracellular signaling pathway and therefore can occlude each other\'s signaling. Indeed, in the presence of dopamine, the serotonin-induced synaptic potentiation was greatly reduced ([@bib25]), suggesting redundancy in their modulatory effects. The functional meaning or the mode of operation of this redundant neuromodulatory system in physiological and pathological conditions remains to be elucidated.

The 5-HT~4~ and D~1~-like receptor signaling at the MF synapse has been extensively investigated by applying exogenous serotonin and dopamine. However, how these receptors are activated by endogenous monoamines remains poorly characterized. Although ECT rapidly and strongly enhances the D~1~-like receptor-dependent synaptic potentiation induced by exogenous dopamine ([@bib28]), whether endogenous dopamine contributes to the effects of ECT remains unknown. Serotonergic fibers abundantly project to the hippocampus ([@bib17]), whereas dopaminergic innervation of the hippocampal dentate gyrus and CA3 region is sparse ([@bib38], [@bib47], [@bib4], [@bib52]). Therefore, endogenous dopamine may contribute little to the modulation of the MF synaptic transmission, which casts doubt on the involvement of the hippocampal dopaminergic system in the neuronal mechanisms underlying ECT and other treatments. However, recent studies have shown that noradrenergic fibers innervating the hippocampus release dopamine in addition to noradrenaline ([@bib20]) and suggested that dopamine derived from the noradrenergic fibers could activate D~1~-like receptor in the hippocampus ([@bib20], [@bib52], [@bib57]). Since noradrenergic fibers densely project to the hippocampus including the CA3 region ([@bib32], [@bib52]), they could be a major source of dopamine for the activation of D~1~-like receptors at the MF synapse.

The present study aimed at revealing how endogenous monoamines modulate the MF synaptic transmission and relevant hippocampal functions, especially focusing on their potential contribution to the mechanism of action of ECT. Our present results suggest a predominant role of serotonin in the modulation of the MF synaptic transmission that may be involved in an anxiolytic action of ECT.

Results {#sec2}
=======

ECT Enhances 5-HT~4~ Receptor-Dependent Synaptic Modulation {#sec2.1}
-----------------------------------------------------------

Chronic antidepressant treatments enhance serotonin- and dopamine-induced synaptic potentiation at the MF synapse ([@bib26], [@bib23]). Although ECT strongly enhances the dopamine-induced synaptic potentiation ([@bib28]) (see [Figure S1](#mmc1){ref-type="supplementary-material"}A), its effect on the serotonin-induced synaptic potentiation remains unknown. Therefore, we first examined the effect of ECT on the serotonin-induced synaptic modulation at the MF synapse. In acute hippocampal slices, bath-applied exogenous serotonin (5-hydroxytryptamine, 5-HT) potentiated synaptic transmission at the MF synapse, as shown previously ([@bib25], [@bib26]). We found that three times of ECT (ECTx3) significantly enhanced this 5-HT-induced synaptic potentiation ([Figures 1](#fig1){ref-type="fig"}A and 1C). The magnitude of synaptic potentiation monotonously increased by repeating ECT up to 11 times ([Figures 1](#fig1){ref-type="fig"}B and 1C). The 5-HT-induced synaptic potentiation at the MF synapse is mediated by the 5-HT~4~ receptor ([@bib25], [@bib26]), a subtype of 5-HT receptor abundantly expressed in the dentate gyrus and along the MF pathway ([@bib56], [@bib14]). In mice lacking the 5-HT~4~ receptor, 5-HT had no significant effect on the synaptic transmission even after 11 times of ECT (ECTx11) ([Figure 1](#fig1){ref-type="fig"}B), indicating that the 5-HT~4~ receptor solely mediates the prominent 5-HT-induced synaptic potentiation in ECT-treated mice. We also examined the effect of ECT on serotonergic synaptic modulation in the CA1 region of the hippocampus. At the Schaffer collateral/commissural fiber-CA1 synapse, 5-HT caused small synaptic potentiation that was dependent on the 5-HT~4~ receptor at least in part ([Figures 1](#fig1){ref-type="fig"}D and 1E). ECTx3 had no significant effect on this synaptic potentiation ([Figures 1](#fig1){ref-type="fig"}D and 1E). These results indicate that ECT enhances the 5-HT~4~ receptor-dependent synaptic modulation in a synapse-specific manner.Figure 1Enhancement of 5-HT~4~ Receptor-Dependent Synaptic Modulation by ECT(A) Effects of ECT repeated three times (ECTx3) on potentiation of MF synaptic transmission induced by 5-HT (5 μM, 5 min) applied in the bath at the horizontal bar. Sample recordings show averages of nine consecutive excitatory postsynaptic potentials (EPSPs) before and at the end of 5-HT application in ECT-treated mice and mice that received three times of control treatments (CNTx3). Scale bar: 10 ms, 0.2 mV.(B) Effects of 11 times of ECT (ECTx11) in normal and 5-HT~4~ knockout (5-HT4-/-) mice. Results of mice treated with 11 times of control treatments (CNTx11) are also shown.(C) Dependence of enhancement of the serotonergic modulation on the number of ECT (Student\'s t test; ECTx3, t~12~ = 3.222, ∗∗p = 0.0073; ECTx11, t~11~ = 16.34, ∗∗∗∗p \< 0.0001).(D) Effects of ECTx3 on 5-HT-induced modulation of synaptic transmission in the CA1 region of wild-type mice.(E) Comparison of the effect of 5-HT on CA1 synapse in wild-type (WT) and 5-HT4-/- mice (one-way ANOVA, F~2,17~ = 6.545, p = 0.0078; Tukey's test ∗∗p = 0.0077).The number (n) of data is shown in the graph in all figures and represents the number of slices in this figure. Data are presented as means ± SEM in all figures.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We then examined the mechanism underlying the enhancement of the 5-HT~4~ receptor-dependent synaptic potentiation by ECT. The rapid change in the phenotype of the dentate gyrus neurons requires glutamate NMDA receptors ([@bib15]). To address the involvement of NMDA receptors, their antagonist CPP was injected before each ECT. Although CPP slightly increased the 5-HT-induced synaptic potentiation, ECTx3 significantly enhanced the 5-HT-induced potentiation in both saline- and CPP-treated mice ([Figure 2](#fig2){ref-type="fig"}A). Although ECTx3 appeared even more effective in the CPP-treated mice, there was no statistically significant interaction between ECT and CPP treatments. These results suggest that NMDA receptor activation is not required for the enhanced 5-HT~4~ receptor-dependent synaptic modulation by ECT. Next, we examined the possibility that increased 5-HT~4~ receptor expression underlies the enhanced synaptic modulation. Since the 5-HT~4~ receptor-dependent synaptic potentiation at the MF synapse is independent of GABA-mediated synaptic inhibition and is mediated by presynaptic mechanisms ([@bib25]), we analyzed the 5-HT~4~ receptor gene expression in the dentate gyrus. In contrast to the prominent enhancement of the synaptic modulation, there was no significant change in the expression level of the 5-HT~4~ receptor gene after single or repeated ECT ([Figure 2](#fig2){ref-type="fig"}B). We also examined a possible change in cAMP-dependent signaling, a downstream cascade of 5-HT~4~ receptor activation ([@bib25]), by using the adenylate cyclase activator forskolin. Bath-applied forskolin (10 μM) greatly potentiated the MF synaptic transmission, and ECTx11 had no significant effect on this forskolin-induced synaptic potentiation ([Figure 2](#fig2){ref-type="fig"}C).Figure 2Induction and Expression Mechanisms of Enhancement of Serotonergic Synaptic Modulation(A) The NMDA receptor antagonist (R)-CPP increased 5-HT-induced synaptic potentiation but did not affect its enhancement by ECT (two-way ANOVA: ECT effect, F~1,20~ = 46.83, p \< 0.0001; CPP effect, F~1,20~ = 12.47, p = 0.0021; interaction ECT × CPP, F~1,20~ = 1.679, p = 0.2098; Sidak\'s test, ∗∗p = 0.0017, ∗∗∗∗p \< 0.0001).(B) No significant effects of ECT on 5-HT~4~ receptor gene expression in the dentate gyrus.(C) No significant effects of ECT on synaptic potentiation induced by forskolin (10 μM). The number (n) of data represents the number of mice in (B) or slices in (A) and (C) of this figure.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Endogenous Serotonin Modulates MF Synaptic Transmission {#sec2.2}
-------------------------------------------------------

We next examined endogenous monoamines involved in the regulation of the MF synaptic transmission using methamphetamine, which can induce the release of monoamines including serotonin and dopamine ([@bib48]). Bath-applied methamphetamine caused slowly developing synaptic potentiation in naive mice. The 5-HT~4~ receptor antagonist GR125487 suppressed this methamphetamine-induced synaptic potentiation by about 85% ([Figures 3](#fig3){ref-type="fig"}A and 3D). On the other hand, the D~1~-like receptor antagonist SCH23390, applied at a concentration sufficient for suppressing the exogenous dopamine-induced potentiation (see [Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib28]), had no significant effect ([Figures 3](#fig3){ref-type="fig"}B and 3D). The dopamine content in the hippocampal slice may be insufficient for activation of D~1~-like receptors at the MF synapse. It is also possible that methamphetamine is not effective in releasing dopamine in the slice preparation. To distinguish between these possibilities, we added the dopamine precursor L-dopa to increase the dopamine content in the slice. In the presence of L-dopa and GR125487, methamphetamine induced robust synaptic potentiation ([Figures 3](#fig3){ref-type="fig"}C and 3D). SCH23390 completely suppressed the methamphetamine-induced synaptic potentiation in the L-dopa-loaded slice ([Figure 3](#fig3){ref-type="fig"}E), suggesting that the extracellular dopamine level was sufficient for activation of D~1~-like receptors in this condition. These results support the former possibility that the hippocampal dopamine content is insufficient for activation of D~1~-like receptors at the MF synapse in the control condition.Figure 3Endogenous Serotonin Potentiates MF Synaptic Transmission(A) MF synaptic potentiation induced by bath-applied methamphetamine (10 μM, 20 min) and its block by the 5-HT~4~ receptor antagonist GR125487 (GR, 40 nM). Scale bar: 10 ms, 0.2 mV. Sample recordings show averages of 30 consecutive EPSPs during baseline and at the peak of potentiation. Stimulus artifacts are truncated.(B) Methamphetamine-induced synaptic potentiation was not affected by the D~1~-like receptor antagonist SCH23390 (SCH, 50 nM).(C) Methamphetamine-induced synaptic potentiation in the presence of L-dopa (5 μM) and GR125487.(D) Summary of effects of methamphetamine (one-way ANOVA, F~2,18~ = 14.82, p = 0.0002; Tukey\'s test ∗∗p = 0.006, ∗∗∗p = 0.0001).(E) Suppression of methamphetamine-induced potentiation in the presence of L-dopa and GR125487 by SCH23390 (Student\'s t test, t~7~ = 8.92, ∗∗∗∗p \< 0.0001). Slices were preincubated in the normal or SCH23390-containing saline and then transferred to the recording chamber perfused with the saline containing L-dopa and GR125487. The number (n) of data represents the number of slices.

We further examined the synaptic modulation by endogenous monoamines in ECT-treated mice. Repeated ECT strongly enhanced the methamphetamine-induced synaptic potentiation ([Figures 4](#fig4){ref-type="fig"}A and 4B). As in the naive mice, GR125487 largely inhibited the methamphetamine-induced potentiation in ECT-treated mice ([Figure 4](#fig4){ref-type="fig"}B), suggesting that ECT enhanced synaptic potentiation caused by endogenous 5-HT acting on the 5-HT~4~ receptor. The effects of endogenous 5-HT depletion were also examined by inhibiting tryptophan hydroxylase (TPH), a rate-limiting enzyme in the 5-HT biosynthesis. The TPH inhibitor 4-chloro-DL-phenylalanine methyl ester (p-chlorophenylalanine, pCPA) significantly reduced the methamphetamine-induced synaptic potentiation in ECT-treated mice ([Figures 4](#fig4){ref-type="fig"}C and 4D), which agrees with the effect of the 5-HT~4~ receptor antagonist GR125487. Furthermore, in 5-HT~4~ receptor knockout mice, the methamphetamine-induced synaptic potentiation was strongly reduced in both control and ECT-treated mice ([Figure S3](#mmc1){ref-type="supplementary-material"}). In the L-dopa-loaded slice, methamphetamine caused robust D~1~-like receptor-dependent synaptic potentiation in the presence of GR125487, as shown above, which was strongly increased by ECTx3 ([Figure 4](#fig4){ref-type="fig"}E). Therefore, although ECTx3 enhanced the D~1~-like receptor-dependent synaptic modulation as well, the dopamine content in the hippocampal slices was insufficient for robust activation of D~1~-like receptors without L-dopa. These results suggest that 5-HT serves as the predominant endogenous monoamine in modulation of the MF synaptic transmission in normal and ECT-treated mice.Figure 4Repeated ECT Enhances Synaptic Potentiation Mediated by Endogenous 5-HT(A) Effects of ECTx3 on synaptic potentiation induced by methamphetamine.(B) Summary of effects of ECT and GR125487 on methamphetamine-induced synaptic potentiation (ECTx3: one-way ANOVA, F~2,14~ = 19.84, p \< 0.0001; CNT versus ECT, p = 0.0006; ECT versus ECT + GR, p = 0.0002; ECTx11: one-way ANOVA, F~2,13~ = 17.42, p = 0.0002; CNT versus ECT, p = 0.0006; ECT versus ECT + GR, p = 0.0007).(C and D) Suppression of methamphetamine-induced synaptic potentiation by the TPH inhibitor p-chlorophenylalanine (pCPA) in ECT-treated mice (Student\'s t test, t~9~ = 4.828, ∗∗∗p = 0.0009). Hippocampal slices were prepared from mice intraperitoneally injected with pCPA (300 mg/kg) and maintained in the saline containing pCPA (200 μM) before recording.(E) Enhancement of methamphetamine-induced potentiation in the presence of L-dopa and GR125487 by ECTx3 (Student\'s t test, t~5~ = 13.85, ∗∗∗∗p \< 0.0001). The number (n) of data represents the number of slices.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

ECT Increases Serotonin Content along the MF Tract {#sec2.3}
--------------------------------------------------

We noted that the effect of ECTx3 on the methamphetamine-induced potentiation was 2- to 3-fold larger than that on 5-HT-induced potentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}A). This result is somewhat contradictory to the above observation that the methamphetamine-induced potentiation is mostly mediated by 5-HT. ECT might have increased the amount of endogenous releasable 5-HT in the hippocampus. To test this possibility, we performed an immunohistochemical analysis of 5-HT levels along the MF tract in the hippocampal CA3 region. Fluorescent immunostaining using an antibody against 5-HT revealed puncta-like structures in the MF projection area (i.e., the stratum lucidum) of the CA3 region ([Figure 5](#fig5){ref-type="fig"}A). These puncta most likely represented the serotonergic nerve terminals. We found that the number of the detectable immunoreactive puncta increased after ECTx3 ([Figure 5](#fig5){ref-type="fig"}B), whereas there was no significant change in the relative fluorescence intensity distribution between control and ECTx3-treated mice ([Figure 5](#fig5){ref-type="fig"}C). These results suggest that ECTx3 increased the amount of endogenous 5-HT in the stratum lucidum. On the other hand, there was no significant change in the number of 5-HT puncta after ECTx11 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). The relative fluorescence intensity distribution shifted downward after ECTx11, likely owing to a trend increase in the number of low-intensity puncta ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). This lack of an obvious effect of ECTx11 on the 5-HT immunoreactivity is consistent with the comparable effects of ECTx11 on 5-HT- and methamphetamine-induced synaptic potentiation shown by electrophysiological methods ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 5Repeated ECT Increases Serotonin Content along MF Tract(A) Representative images of immunoreactivity of 5-HT in the CA3 region of control mice (left) and ECTx3-treated mice (right). The stratum lucidum is indicated by the dashed line. The insets show enlarged images of the areas indicated by the red rectangles. Scale bar: 100 μm.(B) ECTx3 increases the number of 5-HT immunoreactive puncta in the stratum lucidum (Student\'s t test, t~16~ = 3.032, ∗∗p = 0.0079).(C) No significant effect of ECTx3 on cumulative relative probability distributions of the signal intensity of 5-HT immunoreactive puncta.(D and E) Effects of acute tryptophan (TRP, 10 μM) supplementation on methamphetamine-induced synaptic potentiation in control mice (D) (Student\'s t test, t~16~ = 2.643, ∗p = 0.0177) and ECTx3-treated mice (E). Tryptophan was applied in the bath at least 1 h before methamphetamine administration and continuously perfused throughout the recording. The number (n) of data represents the number of slices.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We further examined a possible increase in the amount of endogenous 5-HT after ECTx3. Since TPH is not saturated by the substrate tryptophan in physiological conditions ([@bib46]), an increase in tryptophan availability can increase 5-HT biosynthesis. To test whether a change in tryptophan availability occurred after ECT, TPH saturation was assessed by electrophysiology. In control mice, acute supplementation of tryptophan in the slice preparation significantly increased the methamphetamine-induced potentiation ([Figure 5](#fig5){ref-type="fig"}D), suggesting that TPH is not saturated by endogenous tryptophan in the control condition. In contrast, tryptophan supplementation had no significant effect in ECTx3-treated mice ([Figure 5](#fig5){ref-type="fig"}E). Therefore, TPH appeared to be more saturated by endogenous tryptophan in ECT-treated mice than in control mice. These results support the idea that the tryptophan availability increased after ECT and may explain the increased 5-HT immunoreactive puncta after ECTx3 (see [Discussion](#sec3){ref-type="sec"}).

ECT Has a Rapid Anxiolytic Effect Mediated by 5-HT~4~ Receptor {#sec2.4}
--------------------------------------------------------------

The 5-HT~4~ receptor has been implicated in both antidepressant- and anxiolytic-like behavioral effects in rodents ([@bib33], [@bib53], [@bib58], [@bib2], [@bib39], [@bib6]). Finally, we examined the possible role of the enhanced 5-HT~4~ receptor-dependent synaptic modulation in behavioral effects of ECT using 5-HT~4~ receptor knockout mice. Since we noted during the course of experiments that behavioral effects of ECT critically depended on the number of treatments, we tested the effects of both ECTx3 and ECTx11. Repeated ECT slightly increased the activity level of mice ([Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). In wild-type mice, ECT increased time spent on the open arms and entries into the open arms in the elevated plus maze (EPM) ([Figure 6](#fig6){ref-type="fig"}A) and decreased time spent in the center of the open field (OF) ([Figure 6](#fig6){ref-type="fig"}B). Although the former anxiolytic-like effect was evident after ECTx3, the latter anxiogenic-like effect was revealed after ECTx11 ([Figures 6](#fig6){ref-type="fig"}A and 6B). An antidepressant-like effect in the tail suspension test (TST) was also observed after ECTx11 ([Figure 6](#fig6){ref-type="fig"}C). In 5-HT~4~ receptor knockout mice, the significant effects of ECT were observed in the OF and TST but not in the EPM ([Figures 6](#fig6){ref-type="fig"}D-6F). Three-way ANOVA showed a significant interaction between genotype and treatment in the EPM results ([Table S1](#mmc1){ref-type="supplementary-material"}), suggesting that the anxiolytic-like effect of ECT depends on the 5-HT~4~ receptor. A significant interaction between treatment and the number of treatments was observed in the OF and TST results ([Table S1](#mmc1){ref-type="supplementary-material"}), suggesting that the anxiogenic- and antidepressant-like effects increase with repetition of ECT. The effects of ECT on the dopamine-induced synaptic potentiation were similar between wild-type and 5-HT~4~ receptor knockout mice ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Therefore, it is unlikely that the 5-HT~4~ deficiency affected the monoaminergic neuromodulation at the MF synapse or the efficacy of ECT in a non-specific manner. These results suggest that ECT has a rapid-onset anxiolytic effect that is mediated at least in part by the 5-HT~4~ receptor.Figure 6Effects of ECT on Anxiety- and Depression-Related Behavior(A--C) Effects of ECT on behavior of wild-type mice. (A) Time spent on the open arms (Sidak\'s test, ∗∗p = 0.0019) and relative number of entries into open arms in the elevated plus maze test (∗∗p = 0.005). (B) Time spent in the center of the open field (∗∗∗∗p \< 0.0001). (C) Immobility in the tail suspension test (∗p = 0.0195).(D--F) Effects of ECT on behavior of 5-HT~4~ receptor knockout mice. (D) Time spent on the open arms and relative number of entries into open arms in the elevated plus maze test. (E) Time spent in the center of the open field (∗p = 0.0365). (F) Immobility in the tail suspension test (∗∗p = 0.0016). See [Table S1](#mmc1){ref-type="supplementary-material"} for details of the results of three-way ANOVA. The number (n) of data represents the number of mice.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In the present study, we found that endogenous serotonin plays a predominant role in the monoaminergic modulations of the hippocampal MF synaptic transmission via activation of the 5-HT~4~ receptor. Although the MF synapse appears to be redundantly modulated by 5-HT and dopamine through the common intracellular signaling pathway, the dopaminergic modulation is almost latent in the normal condition likely due to the low dopamine content in the hippocampus, at least around the MF tract. ECT rapidly and selectively enhanced the 5-HT~4~ receptor-dependent synaptic modulation at the MF synapse. ECT also had the rapid anxiolytic-like behavioral effect that was attenuated in the 5-HT~4~ receptor knockout mice. These results suggest that the enhanced 5-HT~4~ receptor-dependent modulation at the MF synapse is a plausible candidate mechanism mediating the anxiolytic effect of ECT.

The serotonergic fibers abundantly project to the hippocampus ([@bib17]). Activation of the serotonergic fibers in brain slices has been shown to potentiate Schaffer collateral/commissural fiber-CA1 synaptic transmission via the 5-HT~4~ receptor ([@bib55]). Consistently, we found that endogenous 5-HT released by methamphetamine can induce robust potentiation of the MF synaptic transmission in hippocampal slices. Although the dopaminergic projection to the hippocampus is sparse, recent studies have suggested that dopamine released from noradrenergic fibers could effectively activate D~1~-like receptors in the hippocampus ([@bib20], [@bib52], [@bib57]). However, we were unable to detect significant contribution of endogenous dopamine to the methamphetamine-induced synaptic potentiation in the control condition. These results suggest the predominant role of endogenous 5-HT in modulating the MF synaptic transmission, although the actual functioning of these monoamines *in vivo* depends on factors that cannot be assessed by methamphetamine, such as firing properties of monoaminergic neurons and the release probability from the nerve ending. Based on the dose-response relationship of exogenous 5-HT-induced synaptic potentiation in the presence of a 5-HT uptake inhibitor ([@bib25]), the peak extracellular 5-HT concentration in the presence of methamphetamine is estimated to be around 60 nM. As for dopamine, this concentration is near the threshold level for inducing detectable synaptic potentiation ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). In addition, the amount of dopamine in the hippocampus is 50-fold smaller than that of 5-HT (see [Figure S3](#mmc1){ref-type="supplementary-material"}A in [@bib59]). Taken together, these results suggest that dopamine released from dopaminergic or noradrenergic fibers by methamphetamine was insufficient for activation of D~1~-like receptors at the MF synapse in our experimental condition. In other words, the D~1~-like receptor-dependent modulation at the MF synapse is latent in the control condition due to a lack of the sufficient amount of endogenous agonists to activate the receptors. Supplementation of L-dopa unveiled a component of methamphetamine-induced synaptic potentiation mediated by dopamine D~1~-like receptors. ECTx3 strongly enhanced this D~1~-like receptor-dependent potentiation, which is consistent with our previous study showing that repeated ECT greatly enhances D~1~-like receptor-dependent synaptic potentiation induced by exogenous dopamine ([@bib28]). Activation of the latent dopaminergic modulation by L-dopa suggests a low rate of L-dopa synthesis in the hippocampus. Indeed, tyrosine hydroxylase, which catalyzes the conversion of tyrosine to dopa, is expressed at low levels in the hippocampus ([@bib40]). Expression or activity of tyrosine hydroxylase in the hippocampus can be enhanced by ischemia ([@bib40]) or stress ([@bib42]). Therefore, the latent dopaminergic modulation may be activated and robustly contribute to potentiation of the MF synaptic transmission in some conditions, possibly in the pathological conditions.

The enhancement of the 5-HT~4~ receptor-dependent neuromodulation by ECT was observed at the MF-CA3 synapses, but not at the Schaffer collateral/commissural fiber-CA1 synapses, in the present study. Previous studies in the CA1 region have shown that repeated ECT had no effect on 5-HT~4~ receptor-dependent somatic depolarization ([@bib16]) or attenuated a 5-HT~4~ receptor-dependent increase in population spikes ([@bib3]). Therefore, ECT enhances the 5-HT~4~ receptor signaling in a synapse and/or cell type-specific manner. A detailed mechanism underlying this MF synapse-specific effect of ECT on the 5-HT~4~ receptor signaling remains unknown. There was no significant change in the expression of the 5-HT~4~ receptor gene in the dentate gyrus after repeated ECT. We have previously shown that chronic treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine enhanced the 5-HT~4~ receptor-dependent synaptic modulation at the MF synapses without affecting 5-HT~4~ receptor ligand binding in the dentate gyrus or along the MF tract ([@bib23]). Thus, an altered 5-HT~4~ receptor expression level is unlikely to underlie the enhanced 5-HT~4~ receptor signaling caused by these treatments. In the present study, we also showed that repeated ECT did not affect the forskolin-induced synaptic potentiation at the MF synapse, which is consistent with the previous study reporting the absence of ECT effects on forskolin-induced cAMP production *in vivo* ([@bib10]). These results suggest that the enhanced 5-HT~4~ receptor signaling by ECT is most likely due to facilitated coupling of the 5-HT~4~ receptor activation to the downstream cAMP signaling pathway.

Our fluorescent immunohistochemical study demonstrated that ECTx3 increased the number of 5-HT immunoreactive puncta in the stratum lucidum in the CA3 region without affecting the fluorescence intensity distribution, suggesting that ECTx3 increased the amount of 5-HT in this area. Consequently, ECT is supposed to increase the amount of 5-HT that can be released by methamphetamine, which can at least partly explain our observation that the effect of ECT on the methamphetamine-induced potentiation was apparently larger than that on exogenous 5-HT-induced potentiation. There was no detectable change in 5-HT uptake efficacy in the hippocampal slice after ECTx3 ([Figure S2](#mmc1){ref-type="supplementary-material"}). Therefore, it is likely that the increased amount of releasable 5-HT can boost the enhancing effect of ECT on the 5-HT~4~ receptor signaling, although we do not have direct evidence for increased extracellular 5-HT levels. The increased 5-HT immunoreactive puncta after ECT may be due to the formation of new serotonergic terminals and/or increased 5-HT content in the existing terminals, resulting in the detection of previously undetectable terminals. In support of the latter possibility, our tryptophan supplementation experiment suggests that TPH is more saturated by the substrate tryptophan after ECTx3, which could lead to enhanced 5-HT biosynthesis. ECT strongly suppresses hippocampal expression of the gene encoding tryptophan dioxygenase (TDO), a tryptophan-metabolizing enzyme ([@bib15]), and thereby may increase hippocampal tryptophan levels. Mice lacking TDO exhibit a dramatic increase in tryptophan levels and a 2-fold increase in 5-HT levels in the hippocampus ([@bib19]). Since the effects of the TDO deficiency may be partly due to suppression of the peripheral tryptophan metabolism, the downregulation of TDO in the hippocampus is predicted to cause a smaller change in the 5-HT content. A previous *in vivo* microdialysis study showed no significant effect of repeated ECT on basal extracellular 5-HT levels in the hippocampus ([@bib11]). A moderate increase in the 5-HT content may have little influence on overall extracellular 5-HT levels that are affected by both release and reuptake of 5-HT. In addition, the effect of ECT on extracellular 5-HT levels may depend on the treatment condition. Indeed, we did not observe clear changes in 5-HT immunoreactivity after ECTx11. ECT increases TPH protein levels in the hippocampus but decreases its enzymatic activity ([@bib31]). Therefore, in some conditions, ECT may not significantly influence 5-HT levels in the hippocampus. It is also possible that ECT preferentially changed the 5-HT content in particular areas of the hippocampus via a subregion-specific effect of ECT on the gene expression ([@bib15]). Such a non-homogeneous change in the 5-HT level may be hardly detected in the bulk hippocampal dialysate.

In the present study, we found that ECT had an anxiolytic-like behavioral effect in mice that was dependent on the 5-HT~4~ receptor and emerged faster than its antidepressant-like effect. The robust and rapid anxiolytic-like effect of ECT was observed in the EPM. Although chronic treatments with the SSRI fluoxetine also enhances the 5-HT~4~ receptor signaling ([@bib26]), our previous behavioral studies performed in the same experimental condition did not detect any anxiolytic-like effects of fluoxetine in this test ([@bib25], [@bib27]). In principle, SSRI influences all serotonergic transmission, and chronic SSRI can enhance the serotonergic transmission in a non-specific manner via downregulation of the inhibitory 5-HT~1A~ autoreceptor ([@bib51]). In contrast, ECT can enhance the 5-HT~4~ receptor signaling in a synapse and/or cell type-specific manner as discussed above. Some serotonergic pathways are involved in promoting anxiety-like behavior ([@bib35], [@bib44]). The synapse and/or cell type-specific effect of ECT may underlie its superior anxiolytic-like effect over SSRI in the EPM. Hippocampal extracellular 5-HT levels can be increased by environmental stimulation. Especially, the aversive condition such as the exposure to the elevated plus maze was suggested to be critical in increasing extracellular 5-HT levels ([@bib45]), which may be relevant to the involvement of the 5-HT~4~ receptor in the anxiolytic-like effect of ECT in the elevated plus maze shown here.

Although ECT is well known as a strong treatment for depression in humans ([@bib13]), it is not commonly used to treat anxiety disorders. SSRIs are considered as the first-line treatment for anxiety disorders. However, SSRIs are not effective for a significant proportion of patients, and their therapeutic action is slow in onset, typically requiring several weeks of treatment ([@bib5], [@bib1]). One treatment option for the medication-resistant patients is ECT ([@bib34], [@bib12], [@bib36], [@bib37]). Our present preclinical finding supports the robust therapeutic efficacy of ECT for anxiety disorders and also suggests its rapid onset of action. The differential behavioral effects of ECT and SSRI observed in the EPM may be relevant to the effectiveness of ECT in the medication-resistant anxiety disorders. Since the anxiogenic-like effect also emerged during repeated ECT, chronic ECT may be unfavorable for treating anxiety disorders in some conditions ([@bib9]). Given the faster emergence of the anxiolytic-like effect than the antidepressant-like effect in mice, an ECT schedule optimized for treatment of depression may not benefit anxiety disorders. The 5-HT~4~ receptor deficiency attenuated the anxiolytic-like, but not antidepressant-like, effect of ECT. Combined use of 5-HT~4~ receptor ligands and ECT may optimize the therapeutic efficacy of ECT for anxiety disorders.

In conclusion, the seemingly redundant monoaminergic modulation at the hippocampal MF synapse is predominantly mediated by 5-HT in normal conditions. Augmentation of this serotonergic synaptic modulation may be involved in the rapid anxiolytic-like behavioral effect of ECT. Activation of the latent dopaminergic modulation (e.g., by L-dopa administration) could be a potential strategy to improve the efficacy of ECT.

Limitations of the Study {#sec3.1}
------------------------

Since our studies were performed in the slice preparation in which the monoaminergic fibers are severed from their cell bodies, the present results may not be directly translated to physiological functions of the hippocampal monoaminergic system *in vivo*. Although we have concluded that 5-HT, rather than dopamine, predominantly regulates MF synaptic transmission, our results do not exclude the possibility that endogenous dopamine significantly contributes to the monoaminergic modulation at the MF synapse *in vivo*. Another limitation of the present study is the use of only normal mice. Given the therapeutic potential of ECT for anxiety disorders, it is worth investigating the serotonergic modulation and its modification by ECT using relevant animal models of these disorders. Since the 5-HT~4~ receptor deficiency itself does not significantly increase anxiety-related behaviors in untreated control mice ([@bib27]; but see [@bib7]), the pathophysiology and therapeutic treatment of anxiety disorders may not be simply explained by impairment and augmentation of 5-HT~4~ receptor-dependent signaling. Further studies are required to clarify these points.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S5 and Table S1
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